Innovent Biologics Tech Stack

Integrated biologics R&D and manufacturing platform focused on oncology and metabolic disease

Pharmaceutical Manufacturing Suzhou, Jiangsu 5,001–10,000 employees Founded 2011 Public Company

Innovent Biologics operates a vertically integrated drug development pipeline in China with 4 approved oncology and immunology products and 19 in-trial candidates. The tech stack—anchored in SAS, NONMEM, GROMACS, and PyTorch—reflects a mature, compute-heavy analytics and molecular modeling operation, while active projects in peptide platforms, bispecific antibodies, and statistical programming infrastructure suggest R&D scale-up rather than early-stage pivot. The hiring mix skews heavily toward senior research and director-level roles, indicating leadership depth in development and formulation rather than sales or operational scaling.

Tech Stack 18 technologies

Core StackSAS PyTorch Python JMP Minitab Excel PowerPoint Monolix NONMEM WinNonlin R CDISC LIMS MES PI System SQL GROMACS Gaussian

What Innovent Biologics Is Building

◆Challenges

Improving team efficiency
Process validation
Optimizing formulation technology platform
Inadequate succession planning
Improving product pipeline management
Reducing investment risk
Optimizing resource allocation
Process technology transfer challenges
Managing global project data
Coordinating cro data transfer

▲Active Projects

Full chain peptide drug development platform
Workflow improvement
Macro program module development
Clinical trial data analysis presentation
Platform system optimization
Bispecific antibody development
High-throughput antibody expression
Brand project implementation
Building a statistical programming technology platform for integrated data processing, analysis, and visualization
Drug formulation innovation platform

Hiring Activity

Steady70 roles · 20 in 30d

Department

Research

Sales

Data

Healthcare

Finance

Manufacturing

Product

Executive

Seniority

Senior

Director

C-Level

Lead

Manager

Intern

Mid

Notable leadership hires: Peptide Drug Lead, Formulation Process Director, Market Access Director, Clinical Development Lead, Marketing Director

Company intelligence

Find more companies like Innovent Biologics by tech stack, pain points and active projects

Get started free

About Innovent Biologics

Innovent Biologics develops and manufactures biopharmaceutical treatments for cancer, metabolic disease, and autoimmune conditions. Founded in 2011 and publicly listed on the Hong Kong Stock Exchange, the company has built a fully integrated pipeline spanning R&D, chemistry/manufacturing controls (CMC), clinical trials, and commercial operations. Four approved products (sintilimab, bevacizumab, adalimumab, rituximab) are marketed in China; five additional assets are in Phase III trials and 14 are in earlier clinical stages. Manufacturing facilities operate under cGMP standards audited by NMPA, FDA, and EMA. Across 5,001–10,000 employees, the company operates primarily from Suzhou with hiring activity in China and the United States.

HeadquartersSuzhou, Jiangsu

Company Size5,001–10,000 employees

Founded2011

Hiring MarketsChina, United States

Frequently Asked Questions

What is Innovent Biologics' drug pipeline?

Four approved products in China (sintilimab, bevacizumab, adalimumab, rituximab) plus 5 assets in Phase III trials and 14 in earlier clinical development across cancer, metabolic, and autoimmune indications.

What technology does Innovent Biologics use for drug development?

Stack includes SAS, NONMEM, GROMACS, PyTorch, R, SQL, and CDISC for pharmacokinetics modeling, molecular simulation, and clinical trial data analysis. Active projects include peptide drug platforms and a statistical programming technology stack for integrated data processing.